Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Benefit of allo SCT for MCL offset by increased risk of mortality, GVHD

Publish date:: March 18, 2020

Key clinical point: Transplant type was identified as an independent risk factors for improved overall survival (OS).

Major finding: Auto stem cell transplantation (SCT) showed improved OS: HR 0.35, P < .05, compared to allo SCT.

Study details: Single center study of 56 patients who underwent transplant as consolidation therapy for MCL.

Disclosures: Study funding, authors conflicts not reported.

Citation:

Naik S et al. Biol Blood Marrow Transplant. 2020 26: S246-S247.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Mantle Cell Lymphoma

Survey quantifies COVID-19’s impact on oncology,

Angiogenesis, SOX11 expression in MCL positively correlate to increased inflammatory infiltrate,

Benefit of allo SCT for MCL offset by increased risk of mortality, GVHD,

RB/RC induction followed by ASCT achieved high rates of durable MCL remissions,

Case report shows MCL presenting as cryoglobulinemic vasculitis,

All Specialties